5'-AGATCAACTGCCTGAACAC-3'.
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Tables S1-S4 Expt. cond.: 5 mM rac-2a, NH4OH 5 M, 15 mg mL -1 LAAD E. coli wet cells, 30 eq. reducing agent, pH 9.6, 37°C, 220 rpm, 7 h. a: by HPLC; b: HCOONH4 5 M has been used in place of NH4OH 5 M; c: side reactions were observed.
NaBH3CN and borane complexes with secondary or tertiary amines did not perform well, while with catalytic transfer hydrogenation (HCOONH4, Pd/C), side reactions such as reduction of the nitro group (and of the C=C bond of cinnamic acid in the case of cascade reactions) were observed. Instead, t-BuNH2:BH3 was found as effective as NH3:BH3, but the latter is more convenient because of its lower cost and higher atom-economy.
S6 Table S2 . AvPAL variants with D-formation activity higher or similar to the wild type (positive hits from the solid-phase screening, verified by HPLC analysis). Table S3 . AvPAL variants with no D-formation activity (negative hits from the solid-phase screening, verified by HPLC analysis). 
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The pET16b-AvPAL plasmid containing the pal gene from Anabaena variabilis, codon-optimised for E. coli, was obtained as described previously. [1] This plasmid was used as a starting template for the production of the AvPAL single-point mutants library (provided by Codexis, Inc.).
The pRSF-DAAO plasmid containing the daao gene from Trigonopsis variabilis was obtained as described previously. [2] The pma gene from Proteus mirabilis, codon-optimised for E. coli, was synthesised by Geneart and cloned in pET-28a (Novagen) at the restriction sites NdeI and HindIII. The resulting pET28a-LAAD plasmid, checked by sequencing, was used to transform competent E. coli cells.
Antibiotics were added where appropriate to the following final concentrations: ampicillin (Amp) 100
μg mL -1 , kanamycin (Kan) 60 μg mL -1 . Solid media were prepared by addition of agar (1.5% w/v) to liquid media.
Transformations of chemically competent cells were performed by incubating plasmid DNA (25-50 ng)
with the cells (1 aliquot) for 30 min on ice before heat shock (42°C, 20 s). SOC medium (1 mL) was immediately added, and the cells were incubated for 1 h at 37°C and 220 rpm. Colonies containing recombinant plasmids were selected on LB-agar plates containing the suitable antibiotic. SigmaFast tablets, Sigma-Aldrich, dissolved in 2 mL KPi buffer 100 mM, pH 8.0 + 2 mL NH4OH 5 M pH 9.6 in an ultrasonic bath and filtered) to a solution of the substrate (1.5 mL, 20 mM in NH4OH 5 M pH 9.6). Quantities are given per membrane. The assay was performed by transferring the membranes to a Petri dish containing a filter paper disk soaked in the assay solution and incubating at room temperature until the colour had developed. Clones were picked with sterile toothpicks and transferred to 96-deep-well plates containing 1 mL of LB medium with ampicillin, and grown overnight at 37°C and 220 rpm.
Solid phase screening of AvPAL variants

Expression of AvPAL variants
A single colony of E. coli BL21(DE3) carrying the pET16b-AvPAL plasmid (with the desired mutation) was used to inoculate LB medium (8 mL) supplemented with ampicillin, which was grown overnight at 37°C and 220 rpm. The starter culture was used to inoculate LB-based autoinduction medium [3] (800 mL, ForMedium TM ) containing ampicillin and glycerol (0.5% v/v) which was incubated at 18°C and 250 rpm for 4 days. The cells were harvested by centrifugation (5,000 rpm, 20 min, 4°C), washed with KPi
